Statement of Larry Corey, MD on the Success of the CAPRISA 004 Microbicide Trial

Tuesday, July 20, 2010 AIDS/HIV News J E 4

VIENNA, July 19 Today's news of a microbicide that significantly reduced HIV infection is an exciting step forward in the fight against HIV. Equally exciting is the news that the microbicide also reduced the rate of infection of the herpes virus (HSV2), as we know that HSV2 infection increases the risk of acquiring HIV.

This study, CAPRISA 004, is a testament to the support and engagement of the women of Durban, South Africa and the commitment of Drs. Salim and Quarraisha Abdool Karim who led the investigative team that conducted the study.

These results also reinforce the importance of trials in humans to investigate the effect of biomedical interventions for HIV and indicate the beginning successes that new technologies are bringing to the fight against HIV.

Dr. Corey is the Co-Director of the Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Research Center, and the Principal Investigator of the HIV Vaccine Trials Network. The Network is supported through a cooperative agreement with the National Institute of Allergy and Infectious Diseases.

For more information: Sarah B. Alexander +1-206-910-3801

SOURCE HIV Vaccine Trials Network


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Microbicide Trial Lifts Hope for Women's HIV Preve...
Solta Medical, Inc. Announces Second Quarter 2010 ...